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228Objective: The study objectivewas to review our first 300 consecutive robotic-assisted mitral repairs performed
from June 2005 to October 2012 and to compare the surgical outcomes of our previously reported initial 120
cases with the subsequent 180 procedures.
Methods: Our initial 120 robotic-assisted mitral repairs were previously reported, and we now compare our
early experience with the recent 180 consecutive procedures for a total of 300 robotic-assisted mitral repairs.
There was no patient selection. Every patient in need of isolated mitral valve repair underwent this procedure.
All patients received an annuloplasty band and 1 or more of the following: leaflet resection, secondary chordal
transposition, or polytetrafluoroethylene neochordal replacement and edge-to-edge repair.
Results: All 300 patients had preoperative echocardiographic findings of severe mitral regurgitation. There were
no differences (P ¼ not significant) between the initial and the recent cohorts for preoperative characteristics,
including age (58.4  10.5 years vs 59.9 years), female gender (35.8% vs 36.1%), ejection fraction (61.9% vs
60.6%), congestive heart failure (35.0% vs 36.7%), creatinine (0.94mg/dL vs 0.98mg/dL), and NewYorkHeart
Association class. The incidence of anterior and posterior leaflet prolapse was similar in both groups, whereas
Barlow syndromewas higher in group 2 (5.8% vs 27.8%). There was 1 (0.33%) hospital mortality and no deaths
in the last 180 cases. Overall, 8 patients (2.7%) required subsequent mitral valve replacement via a median
sternotomy, 6 (5.0%) in the first group and 2 (1.1%) in the second group (P ¼ .06). One patient in each group
hadmitral valve re-repair through a right mini-thoracotomy, and 1 patient in the first group required a mitral valve
replacement via a mini-thoracotomy during the original procedure. Two of the 180 patients had documented
cerebrovascular accident, but both fully recovered clinically. There was no cerebrovascular accident in the last
120 patients. Crossclamp times decreased from 116 minutes to 91 minutes in the second group despite starting
a training program with a junior associate performing part of the procedure at the console in the last 100 cases.
Post-pumpechocardiograms showedno/tracemitral regurgitation in 86.1%of the last 180patients andmildmitral
regurgitation in 11.1%. Follow-up echocardiography for the last 180 patients from 1 month to more than 1 year
showed no/trace mitral regurgitation in 64.6% of patients and mild mitral regurgitation in 23.1% of patients.
Seven patients (10.8%) had moderate mitral regurgitation, and 1 patient (1.5%) had severe mitral regurgitation.
Conclusions: The majority of complications and reoperations occurred early in our experience, especially using
the first-generation da Vinci robot (Intuitive Surgical Inc, Sunnyvale, Calif). The newer da Vinci Si HD system
with the addition of an adjustable left atrial roof retractor together with increased experience has made robotic-
assisted mitral repair of all types of degenerative mitral valve pathology reproducible. The training of young
surgeons in a stepwise fashion in high-volume centers will help to avoid the complications encountered during
the introduction of this technology. (J Thorac Cardiovasc Surg 2014;147:228-35)The gold standard for the treatment of degenerative mitral
valve (MV)disease remains surgical repair. The classic repaire Division of Cardiothoracic Surgery, Cedars-Sinai Medical Center, Los
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The Journal of Thoracic and Cardiovascular Surgdescribed by Carpentier1 with leaflet resection and annulo-
plasty remains the primary technique for mitral repair. Other
techniques, such as the ‘‘American correction’’2 or artificial
chordae, have been introduced with similar success rates. In-
novations in surgical approach over the past 20 years have led
to the development of minimally invasive access to the MV.
Right mini-thoracotomy with endoscopy enhancements has
been used by several groups with outcomes comparable to
those for the traditional sternotomy approach.3-6 Ten years
ago, Felger and colleagues7,8 pioneered the use of the da
Vinci Robotic Surgical System (Intuitive Surgical, Inc,
Sunnyvale, Calif) for MV repair. Their excellent outcomes
and those of others led to an increased use of the robotic
approach to the MV.9-14 In 2005, our group developed aery c January 2014
Abbreviations and Acronyms
MR ¼ mitral regurgitation
MV ¼ mitral valve
TEE ¼ transesophageal echocardiography
Ramzy et al Acquired Cardiovascular Diseaserobotic-assisted MV surgery program. This review describes
our first 300 consecutive robotic-assisted mitral repairs
performed from June 2005 to October 2012, and we compare
the surgical outcomes of our previously reported initial
120 cases9 with the subsequent 180 procedures.A
C
DMATERIALS AND METHODS
From June 2005 to October 2012, 300 patients underwent intent-to-treat
robotic-assisted MV repair. Our selection criteria for robotic-assisted mitral
repair were as follows: (1) inclusion criteria were all patients with mitral
regurgitation (MR), and (2) exclusion criteria were patients requiring
concomitant coronary artery bypass or aortic valve repair/replacement, or
those with fused right pleura. In the last 100 patients, a computed tomogra-
phy scan of the aorta was performed to assess for aortoiliac and ascending
aortic disease. Therewas 1 intraoperative conversion to a rightminithoracot-
omy before completion of the mitral repair. This was due to external instru-
ment conflicts of the robotic arms that could not be resolved because of space
limitations of working in a small right hemithorax. Otherwise, 299 patients
achieved successful completion of the roboticMV repair. The data presented
in this retrospective review were obtained from an institutionally supported
Cardiothoracic Surgery Quality Assurance Database. This data review was
approved by the Cedars–Sinai Institutional Review Board.
Operative Technique
Our current standard practice has been described.9 The first 74 cases were
performed with the original model of the da Vinci Robotic Surgical System.
For these cases, the handle of the atrial septal roof retractor (Cardiovations,
Irvine, Calif)was inserted just lateral to the right intrathoracic artery. The last
226 caseswere performedwith the second-generation daVinci SiHD,with a
fourth articulating arm as a movable left atrial roof retractor.
After the patient is positioned supine with the right side of the chest
elevated, the right lung is deflated, and a 3 to 4-cm right infrathoracic inci-
sion through the fourth or fifth intercostal space is made as theworking port.
Trocars for the robotic instrument arms, 14-gauge angiocatheters for trac-
tion sutures, and a 20F DLP (Medtronic, Inc, Minneapolis, Minn) intracar-
diac sump drain are inserted through a separate stab-wound incision.
The patient is heparinized, and the femoral vessels are cannulated for
cardiopulmonary bypass. A 2-stage venous cannula is placed through the
femoral vein under transesophageal echocardiography (TEE) guidance to
ensure proper placement for venous drainage with vacuum assistance.
The pericardium is incised ventral to the phrenic nerve. A transthoracic
aortic clamp (Scanlan International, Minneapolis, Minn) is positioned
through the third intercostal space in the midaxillary line. An ascending
aortic root vent (DLP 14-gauge 7F; Medtronic, Inc) is placed under direct
vision. The da Vinci robot is positioned to the patient’s left side, and the in-
strument arms are placed endoscopically. Bypass is established, and the pa-
tient is cooled to 32C.Once cold, the crossclamp is positioned and clamped
under endoscopic vision. An amount of 120 mL of cold blood cardioplegia
(Kþ, mannitol, HCO3 mixture) is infused directly through the aortic root.
Then, 200-mL doses of cold antegrade crystalloid cardioplegia are admin-
istered by the anesthesiologist approximately every 20 minutes after cross-
clamping to supplement the initial dose of cold blood cardioplegia. Once
asystole is achieved, a standard left interatrial incision is made with the
robot, and the left atrial roof retractor is positioned for MVexposure.The Journal of Thoracic and CaAll patients received an annuloplasty band and 1 ormore of the following:
leaflet resection, secondary chordal transfer or neochordal replacement, or
edge-to-edge repair. The edge-to-edge repair served as a commissural closure
or in the p1-a1 and p3-a3 location in cases with residual regurgitation after
testing the valve. No edge-to-edge repair was used as a bailout approach.
Follow-up
All surviving patients (n ¼ 299) were examined and clinically evaluated
within2weeks after hospital discharge.Further clinical follow-upwasobtained
through annual questionnaire, direct patient contact, or routine communication
with the referring physicians, including echocardiogram reports. Overall, 97%
of patients had at least 1 follow-up echocardiogram for this review.
Statistical Methods
Numeric variables were summarized as means standard deviations or
medians (ranges). Categoric variables were summarized as frequencies
(percentages). Numeric variables were compared across groups by the
t test or Wilcoxon rank-sum test, as appropriate. Categoric variables
were compared across groups by the Fisher exact test. SAS version 9.2
(SAS Institute, Inc, Cary, NC) was used for all statistical calculations.RESULTS
All 300 patients had preoperative echocardiographic
findings of severe MR. All patients underwent functional
valve assessment by intraoperative TEE, and the valve
pathology was confirmed at operation.
There were no statistically significant differences
between the first 120 patients and the second 180 patients
for preoperative characteristics, including age (58.4 
10.5 years vs 59.9  11.4 years), female gender (35.8%
vs 36.1%), ejection fraction (61.9% vs 60.6%), congestive
heart failure (35.0% vs 36.7%), creatinine (0.94 mg/dL vs
0.98 mg/dL), and New York Heart Association class
(Table 1). The prevalence of anterior leaflet prolapse was
higher in the later cohort (21.7% vs 32.8%, P ¼ .038), as
well as the prevalence of Barlow syndrome (5.8% vs
27.8% P<.0001). In addition, the frequency of leaflet cleft
was higher in the last 180 patients compared with the first
120 patients (8.3% vs 0%, P<.0006).
The type ofMVrepair differed betweengroups.All patients
received an annuloplasty band. There was a significantly
greater use of triangular resection and cleft closures in the
last 180 patients compared with the first cohort (Table 2).
Mitral ring size was larger in the last 180 patients (average
33  3 mm vs 36  3 mm, P<.0001; #37 ATS band [ATS
Medical Inc, Minneapolis, Minn] used in 9.2% vs 24.4% of
repairs and #39 ATS band used in 5.8% vs 23.9% of repairs,
P<.0001). In the last 180 patients, 5 had a previous failed
MitraClip (Abbott Laboratories, Abbott Park, Ill) procedure.
The concomitant left-sided CryoMaze procedure was
similar, 24.2% versus 22.2%. However, there was an
increase in the rate of left atrial appendage exclusion with
a running 4-0 polytetrafluoroethylene suture between the
first group and second group (12.5% vs 22.2%, P ¼ .034).
Crossclamp times decreased from 116  30 minutes in
the first group to 91  22 minutes in the second grouprdiovascular Surgery c Volume 147, Number 1 229
TABLE 1. Background and preoperative characteristics
Variable All 300 cases First 120 cases Second 180 cases P value
Age, y, mean  SD 57.3  11.0 58.4  10.5 59.9  11.4 .24
BMI, kg/m2, mean  SD 25.30  4.01 25.44  3.96 25.20  4.04 .62
Creatinine, mg/dL, mean  SD 0.97  0.35 0.94  0.21 0.98  0.42 .30
EF, mean  SD 61.1%  8.3% 61.9%  8.2% 60.6%  8.4% .20
Female, n (%) 108 (36.0) 43 (35.8) 65 (36.1) .96
NYHA, n (%) .35
Class 1 51 (17.0) 26 (21.7) 25 (13.9)
Class 2 119 (31.7) 43 (35.8) 76 (42.2)
Class 3 114 (38.0) 45 (37.5) 69 (38.3)
Class 4 16 (5.3) 6 (5.0) 10 (5.6)
CHF, n (%) 108 (36.0) 42 (35.0) 66 (36.7) .77
HTN, n (%) 129 (43.0) 47 (39.2) 82 (45.6) .27
Smoke, n (%) 72 (24.0) 30 (25.0) 42 (23.3) .74
DM, n (%) 12 (4.0) 3 (2.5) 9 (5.0) .37
Pre-AF (replacement), n (%) 99 (33.0) 37 (30.8) 62 (34.4) .53
CVA, n (%) 11 (3.7) 4 (3.3) 7 (3.9) >.99
CA, n (%) 37 (12.3) 20 (16.7) 17 (9.4) .074
Prior surgery, n (%) 1 (0.3) 0 (0) 1 (0.6) >.99
Total diseased vessels, n (%) .73
0 291 (97.0) 117 (97.5) 174 (96.7)
1 7 (2.3) 3 (2.5) 4 (2.2)
2 2 (0.7) 0 (0) 2 (1.1)
Numeric variables: t test. Categoric variables: chi-square or Fisher exact test. AF, Atrial fibrillation; BMI, body mass index; CA, cancer; CHF, congestive heart failure;
CVA, cerebrovascular accident; DM, diabetes mellitus; EF, ejection fraction; HTN, hypertension; NYHA, New York Heart Association; SD, standard deviation.
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a training program with a junior associate performing part
of the procedure at the console in the last 100 cases. Our
longest crossclamp time was in group 1, at 221 minutes.
Longer crossclamp times were associated with more com-
plex procedures. Likewise, more complex cases were asso-
ciated with longer pump times. Pump times decreased from
156  43 minutes to 136  30 minutes (P<.0001).
Morbidity and Mortality
No significant differences in major adverse cardiac
events were noted between groups. There was 1 hospital
mortality in group 1 and no deaths in the last 180 cases.
Overall, 8 patients (2.7%) required subsequent MV
replacement via a median sternotomy, 6 (5.0%) in the firstTABLE 2. Repair characteristics
Variable All 3
Mitral prosthetic ring, n (%) 300
Mitral ring size, mm, mean  SD 34.7
Quadrangular resection, n (%) 53
Triangular resection, n (%) 188
Chordal transposition, n (%) 50
Artificial chordae, n (%) 33
Edge-to-edge A1, P1, n (%) 23
Edge-to-edge A3, P3, n (%) 21
Cleft closure, n (%) 16
MitraClip (Abbott Laboratories, Abbott Park, Ill) removal, n (%) 5
N/A, Not available; SD, standard deviation.
230 The Journal of Thoracic and Cardiovascular Surggroup and 2 (1.1%) in the second group (P¼ .06) (Table 3).
There were 6 neurologic events in the overall experience,
with 4 (3.3%) in group 1 and 2 (1.7%) in group 2
(P ¼ .22). Two of the 4 patients in group 1 had persistent
deficits, and the 2 patients in group 2 recovered completely
before hospital discharge. There were no neurologic events
in the last 120 patients.
The use of homologous blood products, including red
blood cells, platelets, and cryotherapy, was similar between
the first and second groups (27.5% vs 28.9%, P ¼ .79)
(Table 3). The incidence of renal failure (creatinine>2.0)
was low in both the first and second groups (2.5% vs
3.3%, P ¼ .75) (Table 3).
There were no femoral artery or vein complications and
no lymphoceles requiring surgical intervention. Hospital00 cases First 120 cases Second 180 cases P value
(100) 120 (100) 180 (100) N/A
 3.0 33.3  2.9 35.9  2.8 <.0001
(17.7) 46 (38.3) 7 (3.9) <.0001
(62.7) 38 (31.7) 150 (83.3) <.0001
(16.7) 15 (12.5) 35 (19.4) .114
(11.0) 26 (21.7) 7 (3.9) <.0001
(7.7) 8 (6.7) 15 (8.3) .66
(7.0) 6 (5.0) 15 (8.3) .36
(5.3) 1 (0.8) 15 (8.3) .003
(1.7) 0 (0) 5 (2.8) .16
ery c January 2014
TABLE 3. Postoperative outcomes and complications
Outcome/complication All 300 cases First 120 cases Second 180 cases P value
30-d mortality, n (%) 1 (0.3) 1 (1.0) 0 (0) .33
Late mortality, n (%) 2 (0.7) 2 (1.7) 0 (0) .16
MI, n (%) 1 (0.3) 1 (0.8) 0 (0) .40
Stroke (neurologic), n (%) 6 (1.7) 4 (2.5) 2 (1.1) .39
Reversible neurologic injury, n (%) 2 (0.7) 1 (0.8) 1 (0.6) >.99
Reoperation for bleed, n (%) 14 (4.7) 7 (5.8) 7 (3.9) .58
Reoperated valve, n (%) 13 (4.3) 10 (8.3) 3 (1.7) .008
Any blood product, n (%) 169 (56.3) 45 (37.5) 124 (68.9) <.0001
pRBC 76 (25.3) 24 (20.0) 52 (28.9) .083
Platelets 85 (28.3) 33 (27.5) 52 (28.9) .79
FFP 155 (51.7) 36 (30.0) 119 (66.1) <.0001
Cryotherapy 4 (1.3) 1 (0.8) 3 (1.7) .65
Infection, n (%) 1 (0.3) 0 (0) 1 (0.6) >.99
Creatinine>2, n (%) 9 (3.0) 3 (2.5) 6 (3.3) .75
AF/flutter (SVT), n (%) 61 (20.3) 18 (15.0) 43 (23.9) .061
New-onset AF/A flutter, n (%) 47 (5.7) 16 (13.3) 31 (17.2) .42
Pleural effusion, n (%) 7 (2.3) 2 (1.7) 5 (2.8) .71
Diaphragm paralysis, n (%) 1 (0.3) 1 (0.8) 0 (0) .40
Needle lost, n (%) 1 (0.3) 1 (0.8) 0 (0) .40
Hospital LOS, mean  SD 6.0  2.9 6.3  3.9 5.8  2.0 .21
Repair failures and second operation
Mitral replacement, sternotomy 8 (2.7) 6 (5.0) 2 (1.1) .063
Mitral replacement, minithoracotomy 1 (0.3) 1 (0.8) 0 (0) .40
Mitral re-repair, sternotomy 2 (0.7 ) 2 (1.7) 0 (0) .16
Mitral re-repair, minithoracotomy 2 (0.7) 1 (0.8) 1 (0.6) >.99
AF, Atrial fibrillation; FFP, fresh-frozen plasma; LOS, length of stay; MI, myocardial infarction; pRBC, packed red blood cells; SD, standard deviation; SVT, supraventricular
tachycardia.
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days, with only 1 [0.8%] patient requiring readmission
within 30 days) and the second group (5.8  2.0 days,
with no readmission) (Table 3). Repair failures requiring a
second operation were reduced from 8.3% in the first group
to 1.7% in the second group (P ¼ .008).
Rare complications, such as diaphragm paralysis and lost
needle, occurred only in the first 120 cases (1 each). Two pa-
tients were subsequently found to have occluded coronaries,
1 in each group. One patient required a stent for kinking of
the proximal obtuse marginal, and 1 patient was not treated
because it was a distal occlusion.Echocardiographic Studies and Patient Follow-up
All 300 patients had severe MR as measured by preoper-
ative transthoracic echocardiogram and confirmed with in-
traoperative TEE. There were 2 patients with post-pump
TEE demonstrating moderately severe MR requiring valve
replacement in group 1 compared with zero patients in
group 2. Mean echocardiographic follow-up was 990 
61 days for group 1 and 267  204 days for group 2.
Post-pump echocardiograms showed no significant
differences in MR grade between groups (P ¼ .43)
(Figure 1 and Table 4). No/trace MR was seen in 82.3%
of patients in group 1 versus 86.1% of patients in group 2.The Journal of Thoracic and CaMild MR was seen in 16.8% of patients in group 1 versus
11.1% of patients in group 2. Follow-up echocardiography
from 1 month to 1 year showed no/trace MR in 64% of pa-
tients in group 1 versus 64.4% of patients in group 2, and
mild MR in 22.7% of patients in group 1 versus 21.7%
of patients in group 2 (Table 4). More than 1-year follow-
up in group 1 showed 7 patients (7.4%) with moderate
MR and 3 patients (3.2%) with severe MR compared
with 2 patients (4.3%) with moderate MR and 2 patients
(4.3%) with severe MR in group 2. Overall, the frequency
of severe MR after 1 year was low at 3.5%, with a rate of
moderate MR of 6.3% (Table 4).
There was 1 death and 10 failed repairs, defined as symp-
tomatic severe MR, in the first 120 patients, whereas there
was no death and 3 failed repairs in the last 180 patients.
In addition, we are following 4 patients experiencing no
symptoms with severe MR in the first cohort and 1 patient
in the later cohort.DISCUSSION
Since October 2000, the use of robotic mitral repair has
steadily grown. Our experience dates back to 2005. All
patients with MR considered repairable were approached
using the da Vinci system. With increasing experience
and improved outcomes compared with the standardrdiovascular Surgery c Volume 147, Number 1 231
FIGURE 1. Echocardiographic follow-up: Severity of mitral regurgitation.
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more complex mitral pathology leading to a greater propor-
tion of patients with bileaflet pathology and Barlow’s dis-
ease. The older da Vinci robotic system was used in the
first 74 cases, which lacked the adjustable fourth arm. The
next-generation system was used in the next 225 cases.
All failed repairs requiring replacements were in patients
performed with the first-generation robot. Using the newerTABLE 4. Echocardiography follow-up: Mitral regurgitation grade
Preoperative Post-p
Overall MR severity in 300 cases (n ¼ 300) (n ¼
None 184 (
Trace 69 (
Mild 40 (
Moderate 5 (
Severe 300 (100) 1 (
First 120 cases (n ¼ 120) (n ¼
MR severity
None 65 (
Trace 33 (
Mild 20 (
Moderate 1 (
Severe 120 (100) 0 (
Second 180 cases (n ¼ 180) (n ¼
MR severity
None 119 (
Trace 36 (
Mild 20 (
Moderate 4 (
Severe 180 (100) 1 (
P value* .06
MR, Mitral regurgitation. *Compares first 120 cases and second 180 cases (Wilcoxon ran
232 The Journal of Thoracic and Cardiovascular Surggeneration da Vinci system greatly improved visualization
and conduct of the operation. The adjustable fourth arm al-
lowed for efficient manipulation of retraction to improve
visualization for any given stitch. Furthermore, the ability
to release retraction and test the valve also increased our
success rate. There was 1 death and 10 failed repairs in
the first 120 patients, whereas there was no death and 3
failed repairs in the last 180 patients. There are 4 patientsump 30 d 1-12 mo >1 y
299) (n ¼ 276) (n ¼ 140) (n ¼ 142)
61.5) 108 (39.1) 46 (32.9) 31 (21.8)
23.1) 80 (29.0) 44 (31.4) 46 (32.4)
13.4) 65 (23.6) 32 (22.9) 51 (35.9)
1.7) 18 (6.5) 14 (10.0) 9 (6.3)
0.3) 5 (1.8) 4 (2.9) 5 (3.5)
119) (n ¼ 110) (n ¼ 75) (n ¼ 95)
54.6) 37 (33.6) 23 (30.7) 21 (22.1)
27.7) 32 (29.1) 25 (33.3) 29 (30.5)
16.8) 29 (26.4) 17 (22.7) 35 (36.8)
0.8) 8 (7.3) 7 (9.3) 7 (7.4)
0) 4 (3.6) 3 (4.0) 3 (3.2)
180) (n ¼ 166) (n ¼ 65) (n ¼ 47)
66.1) 71 (42.8) 23 (35.4) 10 (21.3)
20.0) 48 (28.9) 19 (29.2) 17 (36.2)
11.1) 36 (21.7) 15 (23.1) 16 (34.0)
2.2) 10 (6.0) 7 (10.8) 2 (4.3)
0.6) 1 (0.6) 1 (1.5) 2 (4.3)
9 .065 .67 .72
k-sum test).
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1 patient in the later cohort. One of these patients in the first
group had a P2 triangular resection and placement of an
ATS band with follow-up echocardiograms showing mild
MR. He is currently asymptomatic. The other 3 patients
in group 1 had annular dilatation and were treated with
ATS bands. They currently have moderate MR and are
asymptomatic with medical management. Our practice is
to use a complete ring for these patients because a partial
ring might not provide the best annular stabilization at
different loading conditions. The 2 patients in the second
group with severeMR remain asymptomatic. We had a total
of 9 patients requiring MV replacement for failed repair at
the time of surgery.We performed a sternotomy in 8 of the 9
patients and a minimally invasive mitral replacement in 1
patient. The failure rate and use of sternotomy decreased
between our first 120 and second 180 cases. Our decision
to use a sternotomy in these cases varied from endocarditis
and poor visualization and access. We did not use the robot
for the replacement because we thought we required more
experience before performing robotic MV replacements.
With our increased experience and the experience of other
centers, we are expanding our program to include robotic
MV replacement.15
Learning Curve and Training
Team learning curve also is important when developing a
robotic program. When examining our results, we find that
we had improved success and decreased clamp time in more
complex patients in the last 180 patients compared with the
first 120 patients. In addition, repair failures requiring a sec-
ond operation were reduced in the second era despite the
significantly increased frequency of more complex pathol-
ogy and repairs. The majority of complications and reoper-
ations occurred early in our experience, especially using the
first-generation da Vinci robot. We strongly believe that
team experience and center volume are crucial components
to a successful program and results. For the second cohort,
we began training our new mitral surgeon on the da Vinci
system. This was done in a stepwise fashion until the sur-
geon progressed to performing the entire case. Our overall
success rate was 97%, which is comparable to other large
series7,8,10,13,16; however, when examining our success
rate for the second cohort, it was 99%, demonstrating
improved experience. Furthermore, the success rate in the
second cohort includes the addition of a new robotic
mitral surgeon.
Intuitive Surgical, Inc has developed a pathway for
training surgeons in cardiac surgery described by Ben-Or
and colleagues17 and Chitwood and colleagues.18 The
training starts with an introduction to the system followed
by online system training. The next step is an in-depth
training at one of the training centers followed by observa-
tion of a live procedure. It is then recommended to start theThe Journal of Thoracic and Cainitial case within 60 days preferentially by 2 weeks. Chit-
wood and colleagues18 recommend that a surgeon should
perform at least 1 to 2 robotically assisted procedures every
4 weeks to maintain proficiency.
We believe the described strategy has some limitations.
First, at the end of training, the new robotic surgeon still
has a significant learning curve to overcome and is vulner-
able to making errors or having complications that senior
operators know to avoid and prevent. Second, young staff
may not have yet developed a sufficient practice to have
enough cases to stay proficient and reduce operating room
time. Because of those limitations, we developed a system-
atic approach to robotic training. To reduce the learning
curve and decrease the risk of complications, the procedure
was divided into 5 steps: (1) opening and setup; (2) closure
of left atriotomy; (3) annular sutures (medial aspect); (4)
annular suture (lateral aspect); and (5) leaflet work. Once
all steps were completely mastered, the new surgeon pro-
gressed to performing the entire case. We strongly believe
that this stepwise approach prevents complication and in-
creases case efficiency. Our results demonstrate that
training a new surgeon has no impact on outcomes. Our
data show that training of a new surgeon had little impact
on pump time and no impact on complication rate. This
stepwise approach of training a new surgeon with an estab-
lished robotic surgeon resulted in a shorter learning curve
with the added benefit of preventing complications that
are seen by novice surgeons. Our experience showed that
the learning curve can be effectively reduced by using a
robust training program. When comparing the first case
times for each surgeon, we see a significant difference
(operating room time: 5 hours 29 minutes vs 4 hours 11 mi-
nutes; pump time: 213 minutes vs 130 minutes; and cross-
clamp: 178 vs 90 minutes).
Maintenance of proficiency is an important component to
maintaining good outcomes and a viable robotic program.
This can be difficult for new mitral surgeons because their
practices may not be large enough to perform the 10 to 15
simple repairs at a frequency of 1 to 2 cases per month as
suggested by Ben-Or and colleagues17 and Chitwood and
colleagues.18 We have developed a strategy of developing
a centralized mitral clinic where the patients are seen by
both surgeons and the case is performed by both surgeons,
allowing for maintenance of proficiency, improved experi-
ence and results, and quicker pace than would be achieved
by a new mitral surgeon.
Echocardiographic Results
Post-pump echocardiograms showed no/trace MR in
86.1% of the last 180 cases and mild MR in 11.1%.
Follow-up echocardiography from 1 month showed no/
trace MR in 70.7% of patients and mild MR in 21.7% of
the last 180 patients. Compared with results from other
large centers, our results are comparable albeit at the higherrdiovascular Surgery c Volume 147, Number 1 233
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Dspectrum. Suri and colleagues13 showed an 18% incidence
of mild MR. We hypothesize that scarring over time after
triangular resection may restrict the leaflet and result in
mild MR in the early to mid-term. However, the freedom
from moderate to severe MR at more than 1 year was
91.4% in the second cohort. Our results are comparable
to those of similar large institutions. McClure and
colleagues19 reported an 88% freedom from moderate to
severe MR. We believe that robotic mitral repair offers
excellent outcomes with minimal risk and morbidity.
Complications
We observed a low incidence of major adverse cardiac
events and only 1 death in the entire cohort, which was in
the first 120 patients. Strokes can be devastating, and there
were 6 neurologic events in the overall experience: 4
(3.3%) in group 1 and 2 (1.7%) in group 2. Although 1 pa-
tient had persistent deficits in the first cohort, none had any
residual deficit in the second cohort. There were no neuro-
logic events in the last 120 patients after instituting our
routine use of computed tomography scan to assess for aor-
toiliac disease.
Two occluded coronaries have occurred in this entire se-
ries, 1 in each cohort. Both patients are currently asymp-
tomatic. Both occlusions occurred during the learning
curves of each surgeon. Injury to the circumflex is a recog-
nized complication after mitral surgery. We routinely eval-
uate the coronary arteries with an angiogram or a coronary
angiogram looking for coronary artery disease and for right
or left dominance. We are particularly careful with our
stitches in left dominant coronary systems. We also
examine the postoperative TEE for any wall motion abnor-
malities. Despite this, we had 1 patient with a nearly
occluded obtuse marginal in the first group requiring inter-
vention with a stent and 1 patient in the second cohort with a
distally occluded obtuse marginal requiring no intervention.
Although the number of coronary occlusions is small, they
occur at a higher frequency. This incidence is a result of a
loss of tactile sensation of depth with the robot. This
complication is avoided by using visual clues to prevent
coronary kinking or occlusion. Since the discovery of these
2 patients, we have modified our technique to minimize the
risk for coronary kinking. We use visual clues to gauge
depth and take particular care when approaching the
annulus near the circumflex. We also take less of a bite in
that location to minimize the risk of kinking.
Overall, we have demonstrated improved clinical
outcomes with decreased crossclamp time in a cohort of
patients with more complex mitral pathology. In addition,
mitral repairs in our last 180 patients were more extensive.
The newer da Vinci system together with increased experi-
ence has made robotic MV repair of all types of degenera-
tive MV pathology reproducible and safe. The training of
young surgeons in a stepwise fashion in high-volume234 The Journal of Thoracic and Cardiovascular Surgcenters will help to avoid the complications encountered
during the introduction of this technology and improve
overall results.Study Limitations
This is a single-institution retrospective clinical study
with only 2 surgeons represented. The lack of late follow-
up for the entire cohort is a limitation, but 97% of patients
were seen and echocardiograms were performed at least
once postoperatively, which provide strong support for
our data.CONCLUSIONS
Robotic mitral surgery is safe and effective. Furthermore,
training new mitral surgeons can be done safely and in a
way that reduces the learning curve and eliminates novice
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